B of A Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry maintains a Buy rating on Teva Pharmaceutical Indus (NYSE:TEVA) and raises the price target from $12 to $13.
September 08, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities maintains a Buy rating on Teva Pharmaceutical and raises the price target from $12 to $13.
The raised price target by B of A Securities indicates a positive outlook for Teva Pharmaceutical. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100